Last reviewed · How we verify
Factor XIIa antagonist monoclonal antibody — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
Factor XIIa antagonist monoclonal antibody (Factor XIIa antagonist monoclonal antibody) — CSL Behring.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Factor XIIa antagonist monoclonal antibody TARGET | Factor XIIa antagonist monoclonal antibody | CSL Behring | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Factor XIIa antagonist monoclonal antibody CI watch — RSS
- Factor XIIa antagonist monoclonal antibody CI watch — Atom
- Factor XIIa antagonist monoclonal antibody CI watch — JSON
- Factor XIIa antagonist monoclonal antibody alone — RSS
Cite this brief
Drug Landscape (2026). Factor XIIa antagonist monoclonal antibody — Competitive Intelligence Brief. https://druglandscape.com/ci/factor-xiia-antagonist-monoclonal-antibody. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab